In many tumor models (including breast, lung, and pancreatic cancer), TGF-β1 has been shown to induce de novo HA synthesis and CD44 expression, which leads to the formation of the HA–CD44 complex and its interaction with kinase receptors such as EGFR. This evidence concerns the gene CD44 and pancreatic neoplasm.